Back to top
more

Baxter International (BAX)

(Real Time Quote from BATS)

$22.92 USD

22.92
2,646,300

+0.42 (1.87%)

Updated Aug 7, 2025 11:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.

Zacks Equity Research

Baxter (BAX) Beats on Q3 Earnings, Divests BioPharma Business

by Zacks Equity Research

Baxter (BAX) reports better-than-expected third-quarter earnings and sales. The company completes the divestment of its BioPharma Solution business. It starts reporting under a new operating model.

Shaun Pruitt headshot

3 Medical Products Stocks to Consider as Earnings Approach

by Shaun Pruitt

These top-rated Zacks Medical sector stocks are very attractive ahead of their quarterly reports on Thursday, November 2 with now looking like an ideal time to invest.

Zacks Equity Research

What's in Store for Cardinal Health (CAH) in Q1 Earnings?

by Zacks Equity Research

Cardinal Health's (CAH) first-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical segment.

Indrajit Bandyopadhyay headshot

Medical Product Stocks' Q3 Earnings Due on Nov 1: SYK & More

by Indrajit Bandyopadhyay

Third-quarter results of Medical Product companies are likely to reflect a year-over-year decline. Let's see how SYK, COR, BAX, FMS and XRAY fare this time around.

Zacks Equity Research

Stryker (SYK) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Stryker's (SYK) third-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.

Zacks Equity Research

Cencora (COR) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Cencora's (COR) fiscal fourth-quarter 2023 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

Zacks Equity Research

BAX vs. SYK: Which Stock Is the Better Value Option?

by Zacks Equity Research

BAX vs. SYK: Which Stock Is the Better Value Option?

Zacks Equity Research

Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q3 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) third-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.

Zacks Equity Research

Baxter (BAX) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Baxter's (BAX) third-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

Santanu Roy headshot

NeoGenomics and SolarEdge Technologies have been highlighted as Zacks Bull and Bear of the Day

by Santanu Roy

NeoGenomics and SolarEdge Technologies are part of the Zacks Bull and Bear of the Day article.

Indrajit Bandyopadhyay headshot

3 Medical Device Stocks With Solid Dividend Yield: CAH & Others

by Indrajit Bandyopadhyay

Here we pick three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.

Zacks Equity Research

Baxter's (BAX) New Launch to Enable Earlier Treatment of Eye

by Zacks Equity Research

Baxter's (BAX) latest offering is likely to enable a more digitally-connected primary care examination and support faster diagnosis for earlier treatment of eye conditions.

Andrew Rocco headshot

The 3 Widest Competitive Moats on Wall Street

by Andrew Rocco

Competitive moats symbolize a company's sustainable advantage, protecting it from competitors and external threats. Three standout examples illustrate this principle vividly.

Zacks Equity Research

Reasons to Retain Baxter International (BAX) in Your Portfolio

by Zacks Equity Research

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Zacks Equity Research

Rockwell Medical (RMTI) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Robust product demand and cost-saving initiatives are likely to have boosted Rockwell Medical's (RMTI) second quarter's top line.

Zacks Equity Research

Baxter (BAX) Beats on Q2 Earnings, Revises 2023 EPS Guidance

by Zacks Equity Research

Baxter's (BAX) second-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.

Zacks Equity Research

Baxter (BAX) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Baxter (BAX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Baxter International (BAX) Lags Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of -6.78% and 2.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Baxter (BAX) to Post Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Baxter's (BAX) second-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

Zacks Equity Research

Earnings Preview: Baxter International (BAX) Q2 Earnings Expected to Decline

by Zacks Equity Research

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Baxter's (BAX) New Launch to Support Complex Critical Care Needs

by Zacks Equity Research

Baxter's (BAX) Progressa+ bed for the ICU is expected to enhance workflow and reduce strain on nursing resources.

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks Equity Research

Strength Seen in Valneva SE Sponsored ADR (VALN): Can Its 15.8% Jump Turn into More Strength?

by Zacks Equity Research

Valneva SE Sponsored ADR (VALN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

BAX vs. SYK: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

BAX vs. SYK: Which Stock Is the Better Value Option?

Zacks Equity Research

Ensign Group (ENSG) Beats on Q1 Earnings, Hikes '23 EPS View

by Zacks Equity Research

Ensign Group's (ENSG) first-quarter results benefit from growing skilled services revenues. Management estimates EPS of $4.64-$4.77 for this year, higher than the earlier mentioned $4.60-$4.74.